We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
WST Expands Dublin Facility to Boost Injectable Therapy Capacity
Read MoreHide Full Article
Key Takeaways
WST added a 165,000 sq ft Dublin facility to boost capacity for high-volume injectable therapies.
Expansion supports rising demand in diabetes, obesity, and GLP-1 treatments with advanced automation.
WST enhances the West Vantage platform with integrated manufacturing and development services.
West Pharmaceutical Services (WST - Free Report) recently expanded its Dublin facility with a new 165,000 square foot building, significantly boosting its contract manufacturing capacity. The move is aimed at supporting rising global demand for high-volume injectable therapies, particularly in fast-growing areas like diabetes and obesity.
The expansion strengthens West Pharmaceutical Services’integrated service offering under its West Vantage platform, enabling advanced drug handling, automation and end-to-end development support. This positions the company to better serve pharmaceutical partners while accelerating time-to-market for complex, high-demand therapies.
Likely Trend of WST Stock Following the News
Following the announcement, the company's shares gained 2.2% in yesterday’s trading session. In the year-to-date period, shares have lost 8.9% compared with the industry’s 3% decline. The S&P 500 has lost 4.9% over the same period.
The Dublin expansion strengthens West Pharmaceutical Services’ long-term growth by scaling its capacity in high-demand injectable segments like GLP-1 therapies for diabetes and obesity—one of the fastest-growing areas in pharma. By enhancing its end-to-end contract manufacturing capabilities under West Vantage, WST deepens integration with pharma clients, increases switching costs and secures recurring, high-margin revenue streams. This not only improves visibility on future demand but also positions the company as a critical supply chain partner, supporting sustained revenue growth and margin expansion over time.
WST currently has a market capitalization of $17.67 billion.
Image Source: Zacks Investment Research
More on the News
West Pharmaceutical Services has significantly expanded its Damastown, Dublin facility with the addition of a 165,000 square foot building, aimed at addressing the rapidly growing global demand for high-volume injectable therapies. The expansion is particularly aligned with surging needs in chronic disease segments such as diabetes and obesity, where next-generation GLP-1 treatments are driving substantial volume growth.
By increasing its global capacity for drug handling and delivery solutions, WST is reinforcing its role in ensuring reliability, quality and security of supply for pharmaceutical and biotechnology customers operating at scale.
Beyond incremental capacity, the new facility meaningfully enhances WST’s contract manufacturing capabilities by integrating advanced automation and commercial-scale drug handling into its existing offerings. The site now supports a broader range of services, including device assembly, component molding, packaging, analytical testing and regulatory support, all under its West Vantage platform.
This end-to-end, single-source model enables customers to streamline development and commercialization processes, reduce complexity and accelerate time-to-market. Strategically, the expansion strengthens West Pharmaceutical Services’positioning as a critical partner in the injectable drug delivery ecosystem, particularly as demand rises for complex biologics and high-volume therapies worldwide.Top of Form
Favorable Industry Prospect of WST
Per a report by Grand View Research, the global injectable drug delivery devices market size was valued at $467.5 billion in 2023 and is projected to reach $823.29 billion by 2030, expanding at a CAGR of 8.4% from 2024 to 2030.
The rising prevalence of chronic diseases and increasing technological advancements are driving demand for injectable drug delivery devices. Government initiatives for various injectable drugs for chronic diseases are further fueling the market growth.
Recent Developments by WST
Recently, West Pharmaceutical exited the fourth quarter of 2025 with better-than-expected results. Solid top-line results, along with improvements in organic revenues, were impressive. Robust performance by the Proprietary Products segment was encouraging. Strength in HVP and robust growth in the Biologics and Pharma market units during the reported quarter were also promising. Gross margin expansion and improving organic revenue trends reinforce confidence in the company’s execution capabilities.
WST’s management attributed the strong finish to 2025 to the consistent execution of its growth strategy. The HVP Components business within the Proprietary Products segment supported double-digit growth in adjusted earnings per share. The company expects momentum to carry into 2026, positioning the year as an important period for focused execution and operational discipline aimed at sustaining growth and enhancing long-term value for patients, customers and shareholders.
Bottom of Form
WST’s Zacks Rank & Other Key Picks
Currently, WST carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported fourth-quarter 2025 adjusted EPS of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
WST Expands Dublin Facility to Boost Injectable Therapy Capacity
Key Takeaways
West Pharmaceutical Services (WST - Free Report) recently expanded its Dublin facility with a new 165,000 square foot building, significantly boosting its contract manufacturing capacity. The move is aimed at supporting rising global demand for high-volume injectable therapies, particularly in fast-growing areas like diabetes and obesity.
The expansion strengthens West Pharmaceutical Services’integrated service offering under its West Vantage platform, enabling advanced drug handling, automation and end-to-end development support. This positions the company to better serve pharmaceutical partners while accelerating time-to-market for complex, high-demand therapies.
Likely Trend of WST Stock Following the News
Following the announcement, the company's shares gained 2.2% in yesterday’s trading session. In the year-to-date period, shares have lost 8.9% compared with the industry’s 3% decline. The S&P 500 has lost 4.9% over the same period.
The Dublin expansion strengthens West Pharmaceutical Services’ long-term growth by scaling its capacity in high-demand injectable segments like GLP-1 therapies for diabetes and obesity—one of the fastest-growing areas in pharma. By enhancing its end-to-end contract manufacturing capabilities under West Vantage, WST deepens integration with pharma clients, increases switching costs and secures recurring, high-margin revenue streams. This not only improves visibility on future demand but also positions the company as a critical supply chain partner, supporting sustained revenue growth and margin expansion over time.
WST currently has a market capitalization of $17.67 billion.
Image Source: Zacks Investment Research
More on the News
West Pharmaceutical Services has significantly expanded its Damastown, Dublin facility with the addition of a 165,000 square foot building, aimed at addressing the rapidly growing global demand for high-volume injectable therapies. The expansion is particularly aligned with surging needs in chronic disease segments such as diabetes and obesity, where next-generation GLP-1 treatments are driving substantial volume growth.
By increasing its global capacity for drug handling and delivery solutions, WST is reinforcing its role in ensuring reliability, quality and security of supply for pharmaceutical and biotechnology customers operating at scale.
Beyond incremental capacity, the new facility meaningfully enhances WST’s contract manufacturing capabilities by integrating advanced automation and commercial-scale drug handling into its existing offerings. The site now supports a broader range of services, including device assembly, component molding, packaging, analytical testing and regulatory support, all under its West Vantage platform.
This end-to-end, single-source model enables customers to streamline development and commercialization processes, reduce complexity and accelerate time-to-market. Strategically, the expansion strengthens West Pharmaceutical Services’positioning as a critical partner in the injectable drug delivery ecosystem, particularly as demand rises for complex biologics and high-volume therapies worldwide.Top of Form
Favorable Industry Prospect of WST
Per a report by Grand View Research, the global injectable drug delivery devices market size was valued at $467.5 billion in 2023 and is projected to reach $823.29 billion by 2030, expanding at a CAGR of 8.4% from 2024 to 2030.
The rising prevalence of chronic diseases and increasing technological advancements are driving demand for injectable drug delivery devices. Government initiatives for various injectable drugs for chronic diseases are further fueling the market growth.
Recent Developments by WST
Recently, West Pharmaceutical exited the fourth quarter of 2025 with better-than-expected results. Solid top-line results, along with improvements in organic revenues, were impressive. Robust performance by the Proprietary Products segment was encouraging. Strength in HVP and robust growth in the Biologics and Pharma market units during the reported quarter were also promising. Gross margin expansion and improving organic revenue trends reinforce confidence in the company’s execution capabilities.
WST’s management attributed the strong finish to 2025 to the consistent execution of its growth strategy. The HVP Components business within the Proprietary Products segment supported double-digit growth in adjusted earnings per share. The company expects momentum to carry into 2026, positioning the year as an important period for focused execution and operational discipline aimed at sustaining growth and enhancing long-term value for patients, customers and shareholders.
Bottom of Form
WST’s Zacks Rank & Other Key Picks
Currently, WST carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported fourth-quarter 2025 adjusted EPS of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.